• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RNF2通过TRAF2-NF-κB信号轴诱导髓源性抑制细胞趋化并促进肝细胞癌进展。

RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axis.

作者信息

Liang Manman, Yang Jianghua, Zhang Aiping, Zhong Na, Quan Bin, Wang Zijian, Zhao Wenying, Geng Biao, Gao Yufeng

机构信息

Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.

Department of Infectious Diseases, Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, 241000, Anhui, China.

出版信息

Cancer Immunol Immunother. 2025 Mar 27;74(5):162. doi: 10.1007/s00262-025-04002-6.

DOI:10.1007/s00262-025-04002-6
PMID:40146286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11950572/
Abstract

RING finger protein 2 (RNF2) has been shown to promote tumor growth in various cancer types. However, the immune regulatory function of RNF2 in the tumor microenvironment is unclear. Here, we report that upregulation of RNF2 is positively correlated with the tumor burden and poor prognosis in hepatocellular carcinoma patients and fosters an immunosuppressive microenvironment with increased MDSCs recruitment, and reduced T cell activation. Mechanistically, RNF2 binds with TRAF2 and directly mediates K63-linked TRAF2 ubiquitination. This modification of TRAF2 enables NF-κB hyperactivation in tumor cells, which subsequently induces CXCL1 transcription to enhance MDSCs migration. Furthermore, RNF2 knockout improves responsiveness to anti-PD-1 therapy in immunocompetent mice, as evidenced by enhancing infiltration of CD8T cells into the tumor and a reduction in MDSC levels. Collectively, our experiments support that perturbing RNF2 and targeting MDSCs may afford therapeutic opportunities for hepatocellular carcinoma interception and prevention.

摘要

环指蛋白2(RNF2)已被证明在多种癌症类型中促进肿瘤生长。然而,RNF2在肿瘤微环境中的免疫调节功能尚不清楚。在此,我们报告RNF2的上调与肝细胞癌患者的肿瘤负荷和不良预后呈正相关,并促进免疫抑制微环境,增加髓源性抑制细胞(MDSCs)募集,降低T细胞活化。机制上,RNF2与TRAF2结合并直接介导K63连接的TRAF2泛素化。TRAF2的这种修饰使肿瘤细胞中的核因子κB(NF-κB)过度活化,随后诱导CXC趋化因子配体1(CXCL1)转录以增强MDSCs迁移。此外,RNF2基因敲除提高了免疫健全小鼠对抗程序性死亡蛋白1(PD-1)治疗的反应性,表现为增强CD8+T细胞向肿瘤内浸润以及降低MDSC水平。总体而言,我们的实验支持干扰RNF2并靶向MDSCs可能为肝细胞癌的拦截和预防提供治疗机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/54b683885dae/262_2025_4002_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/0a43253ef234/262_2025_4002_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/9b35b35f067c/262_2025_4002_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/e0d29eb7beb7/262_2025_4002_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/2a39d11ed74b/262_2025_4002_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/2b7b4bff9fc9/262_2025_4002_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/54b683885dae/262_2025_4002_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/0a43253ef234/262_2025_4002_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/9b35b35f067c/262_2025_4002_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/e0d29eb7beb7/262_2025_4002_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/2a39d11ed74b/262_2025_4002_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/2b7b4bff9fc9/262_2025_4002_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ca9/11950572/54b683885dae/262_2025_4002_Fig6_HTML.jpg

相似文献

1
RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axis.RNF2通过TRAF2-NF-κB信号轴诱导髓源性抑制细胞趋化并促进肝细胞癌进展。
Cancer Immunol Immunother. 2025 Mar 27;74(5):162. doi: 10.1007/s00262-025-04002-6.
2
E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.E3 连接酶 TRIM28 通过增强髓系来源抑制细胞的募集促进非小细胞肺癌对 PD-1 抑制剂的耐药性。
J Exp Clin Cancer Res. 2023 Oct 21;42(1):275. doi: 10.1186/s13046-023-02862-3.
3
DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC.DDR2/STAT3 正反馈环路通过上调 PD-L1 和募集 MDSCs 来调节奥沙利铂耐药 HCC 的免疫抑制微环境。
Cell Mol Gastroenterol Hepatol. 2024;18(4):101377. doi: 10.1016/j.jcmgh.2024.101377. Epub 2024 Jul 3.
4
[High RNF7 expression enhances PD-1 resistance of non-small cell lung cancer cells by promoting CXCL1 expression and myeloid-derived suppressor cell recruitment activating NF-κB signaling].[高RNF7表达通过促进CXCL1表达和髓系来源抑制细胞募集激活NF-κB信号增强非小细胞肺癌细胞的PD-1抗性]
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Sep 20;44(9):1704-1711. doi: 10.12122/j.issn.1673-4254.2024.09.10.
5
Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.靶向细胞因子诱导的杀伤细胞与髓系来源抑制细胞在肝癌中的相互作用。
J Hepatol. 2019 Mar;70(3):449-457. doi: 10.1016/j.jhep.2018.10.040. Epub 2018 Nov 9.
6
METTL3-Mediated m6A Modification Regulates the Polycomb Repressive Complex 1 Components BMI1 and RNF2 in Hepatocellular Carcinoma Cells.METTL3介导的m6A修饰调控肝癌细胞中多梳抑制复合物1组分BMI1和RNF2
Mol Cancer Res. 2025 Mar 3;23(3):190-201. doi: 10.1158/1541-7786.MCR-24-0362.
7
USP24 promotes hepatocellular carcinoma tumorigenesis through deubiquitinating and stabilizing TRAF2.USP24 通过去泛素化和稳定 TRAF2 促进肝细胞癌肿瘤发生。
Biochem Pharmacol. 2024 Nov;229:116473. doi: 10.1016/j.bcp.2024.116473. Epub 2024 Aug 8.
8
Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.肝癌内在 CCRK 抑制作用可减弱髓源抑制性细胞的免疫抑制作用,并增强免疫检查点阻断疗效。
Gut. 2018 May;67(5):931-944. doi: 10.1136/gutjnl-2017-314032. Epub 2017 Sep 22.
9
Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation.索拉非尼通过促进PPARα介导的脂肪酸氧化增强了肝癌中髓源性抑制细胞的功能。
Mol Cancer. 2025 Jan 28;24(1):34. doi: 10.1186/s12943-025-02238-5.
10
Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.靶向鲨烯环氧酶可恢复代谢功能障碍相关脂肪性肝炎诱导的肝细胞癌中抗 PD-1 疗效。
Gut. 2024 Nov 11;73(12):2023-2036. doi: 10.1136/gutjnl-2023-331117.

引用本文的文献

1
Identification and validation of ubiquitination-related genes for predicting cervical cancer outcome.用于预测宫颈癌预后的泛素化相关基因的鉴定与验证
Front Genet. 2025 Jul 30;16:1578075. doi: 10.3389/fgene.2025.1578075. eCollection 2025.

本文引用的文献

1
New perspectives on chemokines in hepatocellular carcinoma therapy: a critical pathway for natural products regulation of the tumor microenvironment.探讨趋化因子在肝细胞癌治疗中的新视角:天然产物调控肿瘤微环境的关键途径。
Front Immunol. 2024 Aug 14;15:1456405. doi: 10.3389/fimmu.2024.1456405. eCollection 2024.
2
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.重塑肿瘤免疫微环境以改善基于 CAR-T 细胞的癌症免疫疗法。
Mol Cancer. 2024 Aug 26;23(1):175. doi: 10.1186/s12943-024-02079-8.
3
Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
免疫检查点抑制剂在治疗晚期肝细胞癌中的研究进展。
Front Immunol. 2024 Aug 9;15:1455716. doi: 10.3389/fimmu.2024.1455716. eCollection 2024.
4
The current status and future of targeted-immune combination for hepatocellular carcinoma.肝细胞癌靶向免疫联合治疗的现状与展望。
Front Immunol. 2024 Aug 5;15:1418965. doi: 10.3389/fimmu.2024.1418965. eCollection 2024.
5
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.免疫抑制性肿瘤微环境在肝细胞癌进展、转移及治疗中的作用:从实验台到临床应用
Exp Hematol Oncol. 2024 Aug 1;13(1):72. doi: 10.1186/s40164-024-00539-x.
6
Re-exploration of immunotherapy targeting EMT of hepatocellular carcinoma: Starting from the NF-κB pathway.肝细胞癌上皮-间质转化免疫治疗的再探索:从核因子κB通路开始
Biomed Pharmacother. 2024 May;174:116566. doi: 10.1016/j.biopha.2024.116566. Epub 2024 Apr 16.
7
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion.癌症中的髓源性抑制细胞:克服肿瘤免疫逃逸的治疗靶点。
Exp Hematol Oncol. 2024 Apr 12;13(1):39. doi: 10.1186/s40164-024-00505-7.
8
NF-κB in biology and targeted therapy: new insights and translational implications.生物学与靶向治疗中的核因子-κB:新见解与转化意义
Signal Transduct Target Ther. 2024 Mar 4;9(1):53. doi: 10.1038/s41392-024-01757-9.
9
The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments.肝细胞癌中肿瘤微环境的复杂性及新兴治疗进展
J Clin Med. 2023 Dec 2;12(23):7469. doi: 10.3390/jcm12237469.
10
E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.E3 连接酶 TRIM28 通过增强髓系来源抑制细胞的募集促进非小细胞肺癌对 PD-1 抑制剂的耐药性。
J Exp Clin Cancer Res. 2023 Oct 21;42(1):275. doi: 10.1186/s13046-023-02862-3.